CD10 Expression in Bladder Urothelial Carcinoma is Linked to Both High Tumor Grade and Late Stage

Yıl 2024, Cilt: 15 Sayı: 3, 410 - 415, 25.12.2024

Tuba Devrim

https://doi.org/10.22312/sdusbed.1471574

Öz

Objective. Bladder urothelial carcinoma continues to be a vital problem despite developing treatment options and constitutes a patient group that requires close follow-up with a high recurrence rate. Bladder cancer recurrence following initial resection in patients with pTa and pT1 tumors can reach rates as elevated as 80%. This study aims to examine CD10 immunohistochemical expression in urothelial carcinoma of the bladder and evaluate its relationship with histopathological parameters.

Material and Method. 56 urothelial carcinoma cases taken from the bladder were included in our study. Histopathologically, hematoxylin-eosin (HE) stained sections of each case were re-evaluated and classified according to the current WHO grading system. Within the scope of the study, 57.4% of the cases were high-grade and 42.9% were low-grade urothelial carcinoma.

Results. Positive CD10 expression was detected in 80.4% of cases. A significant correlation was found between CD10 expression and tumor invasion and high histological grade (p˂0.001). Significantly higher CD10 expression was detected in invasive pT1, pT2, and pT3 tumors compared to non-invasive pTa tumors (p=0.003; 0.004, and 0.01, respectively). A significant positive correlation was also found between pT and CD10 (r = 0.43, p = 0.001). No relationship was found between CD10 immunoexpression and overall survival, disease-free survival, and other clinicopathological criteria.

Conclusion. The analysis revealed a robust correlation between CD10 expression and high tumor grade, invasion, and pathological stage in urothelial carcinoma of the bladder. Considering these collective findings, it was deduced that CD10 might play a role in tumor progression within the pathogenesis of bladder cancer.

Key Words: Bladder, Urothelial carcinoma, Immunohistochemistry, CD10

Anahtar Kelimeler

Bladder, Urothelial carcinoma, Immunohistochemistry, CD10

CD10 Expression in Bladder Urothelial Carcinoma is Linked to Both High Tumor Grade and Advanced Stage

Öz

Objective. Bladder urothelial carcinoma continues to be a vital problem despite developing treatment options and constitutes a patient group that requires close follow-up with a high recurrence rate. Bladder cancer recurrence following initial resection in patients with pTa and pT1 tumors can reach rates as elevated as 80%. This study aims to examine CD10 immunohistochemical expression in urothelial carcinoma of the bladder and evaluate its relationship with histopathological parameters.

Material and Method. 56 urothelial carcinoma cases taken from the bladder were included in our study. Histopathologically, hematoxylin-eosin (HE) stained sections of each case were re-evaluated and classified according to the current WHO grading system. Within the scope of the study, 57.4% of the cases were high-grade and 42.9% were low-grade urothelial carcinoma.

Results. Positive CD10 expression was detected in 80.4% of cases. A significant correlation was found between CD10 expression and tumor invasion and high histological grade (p˂0.001). Significantly higher CD10 expression was detected in invasive pT1, pT2, and pT3 tumors compared to non-invasive pTa tumors (p=0.003; 0.004, and 0.01, respectively). A significant positive correlation was also found between pT and CD10 (r = 0.43, p = 0.001). No relationship was found between CD10 immunoexpression and overall survival, disease-free survival, and other clinicopathological criteria.

Conclusion. The analysis revealed a robust correlation between CD10 expression and high tumor grade, invasion, and pathological stage in urothelial carcinoma of the bladder. Considering these collective findings, it was deduced that CD10 might play a role in tumor progression within the pathogenesis of bladder cancer.

Key Words: Bladder, Urothelial carcinoma, Immunohistochemistry, CD10

Anahtar Kelimeler

Bladder, Urothelial carcinoma, Immunohistochemistry, CD10

Destekleyen Kurum

Yoktur

Kaynakça

• 1. Shukla SK, Chandra S, Chauhan N, Sarpal R. Expression of CD10 in urothelial carcinoma of the bladder and its correlation with histopathological grade, pathological stage, and survival of patients. J Cancer Res Ther. 2021;17(4):887-92. doi:10.4103/jcrt.JCRT_619_18.
• 2. Mishra D, Singh S, Narayan G. Role of B cell development marker CD10 in cancer progression and prognosis. Mol Biol Int. 2016;2016:4328697. doi:10.1155/2016/4328697.
• 3. Al-Maghrabi J. CD10 expression in urinary bladder urothelial carcinoma is associated with high-tumor grade and stage. Pak J Med Sci. 2023;39(1):192–7. doi:10.12669/pjms.39.1.6268.
• 4. Wlodek J. Clinical significance of CD10 expression in cancer. Int Clin Pathol J. 2017;5(1):192-194. doi:10.15406/icpjl.2017.05.00121.
• 5. Bahadir B, Behzatoglu K, Bektas S, Bozkurt ER, Ozdamar SO. CD10 expression in urothelial carcinoma of the bladder. Diagn Pathol. 2009;4:38. doi:10.1186/1746-1596-4-38.
• 6. Ho ME, Quek SI, True LD, Seiler R, Fleischmann A, Bagryanova L, et al. Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2. Oncotarget. 2016;7:15747–56.
• 7. Arber DA, Weiss LM. CD10: a review. Appl Immunohistochem Mol Morphol. 1997;5:125-140.
• 8. Kandemir NO, Bahadır B, Gün BD, Yurdakan G, Karadayı N, Özdamar ŞO. CD10 expression in urothelial bladder carcinomas: staining patterns and relationship with pathologic parameters. Turk J Med Sci. 2010;40(2):3.
• 9. Shukla SK, Chandra S, Chauhan N, Sarpal R, Kusum A, et al. Staining pattern and intensity of CD10 expression in urothelial carcinoma and its prognostic significance. IP Arch Cytol Histopathol Res. 2019;4(1):70-74. doi:10.18231/2456-9267.2019.0012.
• 10. Omran OM. CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma. J Environ Pathol Toxicol Oncol. 2012;31(3):203-212. doi:10.1615/jenvironpatholtoxicoloncol.v31.i3.20.
• 11. Salahaldeen MA, Hasson AH, Jumaa QB, Kassim CM. CD10 and CA19.9 immunohistochemical expression in transitional cell carcinoma of the urinary bladder. Urol Ann. 2013;5(2):81-85.
• 12. Popov H, Ghenev P. Expression of CD10 as a prognostic and predictive factor in urothelial carcinomas. Trakia J Sci. 2015;13:144-146.
• 13. Kumagai-Togashi A, Uozaki H, Kikuchi Y, Watabe S, Numakura S, Watanabe M. Tumorous CD10 is more strongly related to the progression of urothelial carcinoma than stromal CD10. Anticancer Res. 2019;39(2):635–40. doi:10.21873/anticanres.13157.
• 14. Atique M, Abbasi MS, Jamal S, Khadim MT, Akhtar F, Jamal N. CD10 expression intensity in various grades and stages of urothelial carcinoma of urinary bladder. J Coll Physicians Surg Pak. 2014;24(5):351-355.
• 15. Bircan S, Candir O, Kapucuoglu N, Serel TA, Ciris M, Karahan N. CD10 expression in urothelial bladder carcinomas: a pilot study. Urol Int. 2006;77:107-113. doi:10.1159/000093901.
• 16. Abdou AG. CD10 expression in tumour and stromal cells of bladder carcinoma: an association with bilharziasis. APMIS. 2007;115(11):1206-1218. doi:10.1111/j.1600-0643.2007.00645.x.
• 17. Hussien MT, Helmy E, Elsaba TM, Elkady A, Alrefai H, Hetta HF. Assessing CD10 expression level and its prognostic impact in Egyptian patients with urothelial carcinoma. Asian Pac J Cancer Prev. 2020;21(6):1573-1583. doi:10.31557/APJCP.2020.21.6.1573.